Patents Assigned to Shionogi & Co., Ltd.
  • Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
    Patent number: 11345716
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: May 31, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Hiroyuki Tobinaga, Koji Masuda, Satoshi Kasuya, Masanao Inagaki, Manami Masuda
  • NANOPARTICLE COMPOSITION WITH REDUCED CONTAMINANT AND PRODUCTION METHOD THEREOF
    Publication number: 20220160634
    Abstract: A method for the production of the present disclosure comprises: a) a step of agitating a mixture containing a material to be ground, beads and a dispersion medium in a bead mill; and b) a step of adjusting the pH of the mixture. This method reduces a contamination caused by grinding process using a bead mill.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 26, 2022
    Applicants: Shionogi & Co., Ltd., HIROSHIMA METAL & MACHINERY CO., LTD.
    Inventors: Hironori TANAKA, Yuya OCHII, Tetsuharu IBARAKI
  • DIHYDROPYRAZOLOPYRAZINONE DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY
    Publication number: 20220135577
    Abstract: The present invention provides a compound represented by a following formula. A compound represented by, wherein R1 is hydrogen, hydroxy, or the like; R2a and R2b may be taken together with an adjacent carbon atom to form ring B, ring B is a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle; R3a is hydrogen, halogen, hydroxy, or the like; R3b is hydrogen, halogen, hydroxy, or the like; R4a is a group represented by formula: L3 is a single bond or substituted or unsubstituted alkylene, R7 is hydrogen, halogen, hydroxy, or the like, and R4b is halogen, cyano, carboxy, or the like, or its pharmaceutically acceptable salt.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 5, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yusuke TATENO, Manabu KATOU, Toshihiro WADA
  • Medicinal composition for inhalation
    Patent number: 11304937
    Abstract: The present invention provides a particle comprising pirfenidone and a lipid, particularly magnesium stearate, and having a mean particle diameter of 5 ?m or less, and a powder formulation comprising the particle and a carrier.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: April 19, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takeshi Funaki, Yukiko Nishino, Yuki Masuda, Koichi Tsubone
  • Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
    Patent number: 11306106
    Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: April 19, 2022
    Assignee: Shionogi & Co., Ltd.
    Inventor: Makoto Kawai
  • Stereoselective process for preparing substituted polycyclic pyridone derivatives
    Patent number: 11286262
    Abstract: The present invention provides industrially suitable processes for preparing intermediates in the production of substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity. In the process as shown below, wherein each symbol is as defined in the specification, an optically active substituted tricyclic pyridone derivative of the formula (VII) is obtained in high yield and high enantioselectivity by subjecting a compound of the formula (III) or (VI) to intramolecular cyclization with controlling stereochemistry to obtain a compound of the formula (IV) having a removable functional group on an asymmetric carbon, and then removing the functional group thereof.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 29, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Kazuya Okamoto, Tatsuhiko Ueno
  • FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY
    Publication number: 20220073518
    Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 10, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kouhei NODU, Yusuke TATENO, Kengo MASUDA, Yuji NISHIURA, Yoshikazu SASAKI, Yu HINATA
  • Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity
    Patent number: 11267823
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: March 8, 2022
    Assignees: SHIONOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Novel Anti-CCR8 Antibody
    Publication number: 20220064312
    Abstract: Disclosed is a novel anti-CCR8 antibody. The antibody can be used for treating or preventing cancers or the like.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 3, 2022
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Mai Yoshikawa, Tatsuya Takahashi, Junji Onoda, Sunao Imai, Etsuo Nakamura, Kentaro Furukawa, Tsuguo Miyauchi, Tetsuya Yoshida, Morio Nagira, Naganari Ohkura, Atsushi Tanaka, Shimon Sakaguchi, Hisashi Wada, Atsunari Kawashima
  • Process for preparing substituted polycyclic pyridone derivative and crystal thereof
    Patent number: 11261198
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: March 1, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Setsuya Shibahara, Kosuke Anan
  • MEDICAMENT FOR THE TREATMENT OF CHRONIC COUGH
    Publication number: 20210393640
    Abstract: Provided is a pharmaceutical composition for treating chronic cough, which has substantially no side effects of taste disturbance. A pharmaceutical composition for treating chronic cough, comprising a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 4, 2019
    Publication date: December 23, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Ryuta TAMANO, Erika KASAl, Sayaka MIYAZAKI, Katsue MAGARI
  • Fused ring derivative having MGAT-2 inhibitory activity
    Patent number: 11198695
    Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: December 14, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Kouhei Nodu, Yusuke Tateno, Kengo Masuda, Yuji Nishiura, Yoshikazu Sasaki
  • BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20210317125
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.
    Type: Application
    Filed: June 16, 2021
    Publication date: October 14, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Koji MASUDA, Shuichi SUGIYAMA, Toru YAMADA, Eiichi KOJIMA, Tomoyuki OGAWA, Naotake KOBAYASHI, Hiroyuki KAI
  • Method for the treatment or prevention of a disease related to vascular endothelial lipase by administering a humanized monoclonal antibody
    Patent number: 11136411
    Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 5, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Hiroaki Aino, Etsuo Nakamura, Sunao Imai, Shoji Yamane
  • Manufacturing process of formulation having improved content uniformity
    Patent number: 11135217
    Abstract: The present invention offers the manufacturing method of the solid formulation wherein the standard deviation of the active ingredient content in the solid formulation becomes 5% or less by mixing the excipients which have a median particle size of 15 or more times, preferably 20 times or more to the median particle size of an active ingredient.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: October 5, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Mashimo, Shunji Ichio
  • 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20210292283
    Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p 1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 23, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Satoru TANAKA, Tomoyuki OGAWA, Hiroyuki KAI, Yuki OGATA, Keiichiro HIRAI, Noriyuki KUROSE, Yasuhiko FUJII
  • ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE
    Publication number: 20210292321
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
    Type: Application
    Filed: June 29, 2019
    Publication date: September 23, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.
    Inventors: Akihiro ISHII, Akihiko SATO, Makoto KAWAI, Yoshiyuki TAODA
  • 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same
    Patent number: 11124486
    Abstract: A compound represented by Formula (I): wherein or the like, Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like, Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 21, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tomoyuki Ogawa, Hiroyuki Kai, Keiichiro Hirai
  • Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
    Patent number: 11116727
    Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 14, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Mashimo, Shunji Ichio
  • PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND CRYSTAL THEREOF
    Publication number: 20210230187
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 29, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Setsuya SHIBAHARA, Nobuaki FUKUI, Toshikatsu MAKI, Kosuke ANAN